免疫療法

論文紹介

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study

Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet medical
need. The standard-of-care therapy comprises curative-intent platinum-based chemotherapy
with concurrent radiotherapy (cCRT), which can be followed by prophylactic brain irradiation
and then observation. However, most patients will develop a relapse. Durvalumab (antiprogrammed
cell death ligand-1) has enhanced the efficacy outcomes after cCRT for patients with
unresectable, stage III, non-SCLC. Recently, durvalumab combined with platinum-etoposide
demonstrated a significant survival benefit compared with platinum-etoposide as first-line
treatment of extensive-stage SCLC and has also shown antitumor activity as monotherapy
and combined with tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4) in
pretreated patients with extensive-stage SCLC.

2020-01-29
Clin Lung Cancer